By Suherman Candra Maholtra 
A significant breakthrough in the field of oncology has emerged from a Phase 1 clinical trial, revealing that a redesigned immunotherapy drug can not only shrink targeted tumors but also trigger a systemic immune response that eliminates cancer throughout the body. The study, recently published in the journal Cancer Cell, details the success of a modified CD40 agonist antibody known as 2141-V11. Developed by researchers at Rockefeller University and tested in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), the treatment has demonstrated the ability to induce complete remission in patients with aggressive, metastatic cancers while avoiding the severe toxicities that have plagued similar therapies for decades.
For more than 20 years, the medical community has viewed the CD40 receptor as a "holy grail" for cancer immunotherapy. CD40 is a protein found on the surface of antigen-presenting cells, such as dendritic cells, which play a crucial role in "teaching" the immune system to recognize and attack foreign invaders, including cancer. By activating this receptor, scientists hoped to unleash a potent, targeted immune assault on tumors. However, early versions of CD40 agonist antibodies were hampered by a narrow therapeutic window. When administered intravenously, these drugs often caused widespread systemic inflammation, liver damage, and a dangerous drop in blood platelets (thrombocytopenia), even at doses too low to effectively kill the cancer.
The Evolution of CD40 Therapy and the 2018 Breakthrough
The path to the current clinical success began in the laboratory of Jeffrey V. Ravetch at Rockefeller University. Recognizing that the delivery method and the molecular structure of previous CD40 antibodies were flawed, Ravetch’s team spent years re-engineering the molecule. In 2018, the team published a seminal paper in the Proceedings of the National Academy of Sciences (PNAS), outlining a new design for the antibody.
The researchers discovered that for a CD40 antibody to be effective, it required a specific type of "crosslinking" with Fc receptors on neighboring cells. By modifying the "tail" or Fc region of the antibody, they were able to enhance its ability to bind to the FcγRIIB receptor. This modification made the drug roughly ten times more potent in stimulating an immune response compared to its predecessors. Furthermore, the team proposed a shift in administration: rather than infusing the drug into the bloodstream, where it could cause systemic harm, they would inject it directly into a single accessible tumor. This intratumoral approach was designed to concentrate the drug where it was needed most, minimizing exposure to healthy tissues.
Phase 1 Trial Results: A Remarkable Success Rate
Following the successful preclinical trials in humanized mice, the drug 2141-V11 moved into a Phase 1 clinical trial to test its safety and efficacy in humans. The study involved 12 participants, all of whom suffered from metastatic cancers that had resisted conventional treatments. The cohort included patients with melanoma, renal cell carcinoma, and various forms of breast cancer.
The results exceeded the researchers’ expectations. Out of the 12 patients, six experienced significant tumor shrinkage—a 50% response rate, which is unusually high for a Phase 1 trial involving heavily pre-treated patients. Most notably, two of these patients achieved complete remission, with no detectable traces of cancer remaining in their bodies.
"Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable," said Dr. Juan Osorio, the study’s first author and a medical oncologist at Memorial Sloan Kettering Cancer Center. Osorio, who also serves as a visiting assistant professor in Ravetch’s Leonard Wagner Laboratory, emphasized that the lack of severe side effects was a primary milestone. Unlike previous CD40 trials, participants in this study experienced only mild toxicity, proving that the localized injection strategy successfully mitigated systemic danger.
The Abscopal Effect: Local Injection, Systemic Response
One of the most profound observations during the trial was the occurrence of the "abscopal effect." This phenomenon refers to a situation where localized treatment of a single tumor leads to the shrinkage of distant, untreated tumors elsewhere in the body. In the case of 2141-V11, the immune system, once "educated" at the site of the injection, sent T cells to hunt down and destroy cancer cells in other organs.
Dr. Ravetch highlighted the case of a melanoma patient who presented with dozens of metastatic lesions on her leg and foot. The clinical team injected only one tumor on her thigh. Following a series of injections into that single site, all other tumors on her limb disappeared. A similar outcome was observed in a patient with metastatic breast cancer. Although the drug was only injected into a skin lesion, the patient’s metastatic tumors in the liver and lungs were also eliminated.
"This effect—where you inject locally but see a systemic response—that’s not something seen very often in any clinical treatment," Ravetch noted. "It’s another very dramatic and unexpected result from our trial."
Biological Transformation: Turning Tumors into "Immune Hubs"
To understand why the drug was so effective, the research team analyzed biopsies from the treated tumors. They discovered that the 2141-V11 antibody had fundamentally transformed the tumor microenvironment. Under the influence of the drug, the tumors became densely packed with various immune cells, including T cells, B cells, and dendritic cells.
These cells organized themselves into "tertiary lymphoid structures" (TLS). These structures resemble miniature lymph nodes and act as local command centers for the immune system within the tumor itself. The presence of TLS is a well-known biomarker for positive outcomes in cancer patients, as they facilitate a sustained and organized immune attack.
"The drug creates an immune microenvironment within the tumor and essentially replaces the tumor with these tertiary lymphoid structures," Osorio explained. Crucially, these structures were also detected in tumors that had not been directly injected, confirming that the immune system had successfully "migrated" the anti-cancer response to distant sites.
Institutional Support and the Funding Timeline
The development of 2141-V11 was made possible through a unique funding model at Rockefeller University. The research was supported by the Rockefeller Therapeutic Development Fund, an initiative designed to bridge the gap between laboratory discovery and clinical application—a stage often referred to as the "valley of death" in drug development.
The fund was established by the late philanthropist and Rockefeller trustee Julian Robertson and has since been sustained by the Black Family Foundation. This support allowed the researchers to maintain control over the drug’s development and ensure that the engineering stayed true to the biological insights discovered in the lab. The transition from the 2018 PNAS report to the 2024 publication in Cancer Cell represents a rapid and successful translation of basic science into a potentially life-saving clinical tool.
Future Outlook: Expanding to Hard-to-Treat Cancers
The success of the Phase 1 trial has paved the way for more extensive studies. Currently, nearly 200 patients are enrolled in expanded Phase 1 and Phase 2 trials. These studies are exploring the efficacy of 2141-V11 against some of the most challenging malignancies in modern medicine, including:
- Glioblastoma: An aggressive form of brain cancer with few effective treatment options.
- Prostate Cancer: Specifically forms that have become resistant to hormone therapy.
- Bladder Cancer: Exploring the drug’s potential in both early and metastatic stages.
The ongoing trials are also focused on identifying "biomarkers of response." The researchers noted that the two patients who achieved complete remission both started the trial with a high "clonality" of T cells, suggesting their immune systems were already primed to recognize the cancer, but lacked the necessary signal to act.
"As a general rule, only 25 to 30% of patients will respond to immunotherapy," Osorio stated. "The biggest challenge in the field is to try to determine which patients will benefit from it. What are the indicators or predictors of response? And how can we convert non-responders into responders?"
Implications for the Field of Immunotherapy
The implications of this study extend beyond CD40 antibodies. It validates the concept that "local is systemic" in immunotherapy, suggesting that many potent drugs currently deemed too toxic for intravenous use might be safely and effectively administered through direct injection.
Furthermore, the ability of 2141-V11 to generate tertiary lymphoid structures provides a new target for researchers looking to "heat up" cold tumors—cancers that the immune system normally ignores. By turning a tumor into its own destruction site, scientists may have found a way to bypass the natural defenses that cancers use to hide from the body’s T cells.
As the medical community awaits the results of the larger Phase 2 trials, the early data on 2141-V11 offers a beacon of hope. For patients with metastatic disease who have exhausted traditional therapies, the prospect of a localized injection resulting in a total body cure represents a new frontier in the fight against cancer. The collaboration between Rockefeller University, MSKCC, and Duke University continues to refine this therapy, with the goal of making complete remission a reality for a much larger percentage of the patient population.